Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan E Bates

Showing results (171-180 of 293) with videos related to

Pageof 30
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2010
New strategies in peripheral T-cell lymphoma: understanding tumor biology and developing novel therapiesKieron Dunleavy, Richard L Piekarz, Jasmine Zain, et al.
Journal of Natural Products|February 1, 2011
Flavonoids from eight tropical plant species that inhibit the multidrug resistance transporter ABCG2Muhammad Ali Versiani, Thushara Diyabalanage, Ranjala Ratnayake, et al.
Cancer Chemotherapy and Pharmacology|April 20, 2005
Single nucleotide polymorphisms modify the transporter activity of ABCG2Kuniaki Morisaki, Robert W Robey, Csilla Ozvegy-Laczka, et al.
Discovery Medicine|January 31, 2012
Transporter pharmacogenetics: transporter polymorphisms affect normal physiology, diseases, and pharmacotherapyTristan M Sissung, Sarah M Troutman, Tessa J Campbell, et al.
Cancer Biology & Therapy|November 30, 2012
Histone deacetylase inhibitors induce CXCR4 mRNA but antagonize CXCR4 migrationCaterina Ierano, Agnes Basseville, Kenneth K W To, et al.
Molecular Cancer Therapeutics|December 20, 2007
Novel E-ring camptothecin keto analogues (S38809 and S39625) are stable, potent, and selective topoisomerase I inhibitors without being substrates of drug efflux transportersKazutaka Takagi, Thomas S Dexheimer, Christophe Redon, et al.
Breast Cancer Research and Treatment|November 13, 2023
Analysis of data from the PALOMA-3 trial confirms the efficacy of palbociclib and offers alternatives for novel assessment of clinical trialsCeline Yeh, Mengxi Zhou, Neil Bapodra, et al.
Cancers|December 30, 2025
CA19-9 as a Dynamic Biomarker for Continuous Monitoring of Therapeutic Efficacy in Pancreatic AdenocarcinomaLuigi Brancato, Damar Osok, Laurent Van den Bossche, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 23, 2013
Overlapping substrate and inhibitor specificity of human and murine ABCG2Joshua Bakhsheshian, Matthew D Hall, Robert W Robey, et al.
Blood|March 5, 2004
T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistanceRichard L Piekarz, Robert W Robey, Zhirong Zhan, et al.
Pageof 30

Showing results (171-180 of 293) with videos related to

Sort By:
Pageof 30
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2010
New strategies in peripheral T-cell lymphoma: understanding tumor biology and developing novel therapiesKieron Dunleavy, Richard L Piekarz, Jasmine Zain, et al.
Journal of Natural Products|February 1, 2011
Flavonoids from eight tropical plant species that inhibit the multidrug resistance transporter ABCG2Muhammad Ali Versiani, Thushara Diyabalanage, Ranjala Ratnayake, et al.
Cancer Chemotherapy and Pharmacology|April 20, 2005
Single nucleotide polymorphisms modify the transporter activity of ABCG2Kuniaki Morisaki, Robert W Robey, Csilla Ozvegy-Laczka, et al.
Discovery Medicine|January 31, 2012
Transporter pharmacogenetics: transporter polymorphisms affect normal physiology, diseases, and pharmacotherapyTristan M Sissung, Sarah M Troutman, Tessa J Campbell, et al.
Cancer Biology & Therapy|November 30, 2012
Histone deacetylase inhibitors induce CXCR4 mRNA but antagonize CXCR4 migrationCaterina Ierano, Agnes Basseville, Kenneth K W To, et al.
Molecular Cancer Therapeutics|December 20, 2007
Novel E-ring camptothecin keto analogues (S38809 and S39625) are stable, potent, and selective topoisomerase I inhibitors without being substrates of drug efflux transportersKazutaka Takagi, Thomas S Dexheimer, Christophe Redon, et al.
Breast Cancer Research and Treatment|November 13, 2023
Analysis of data from the PALOMA-3 trial confirms the efficacy of palbociclib and offers alternatives for novel assessment of clinical trialsCeline Yeh, Mengxi Zhou, Neil Bapodra, et al.
Cancers|December 30, 2025
CA19-9 as a Dynamic Biomarker for Continuous Monitoring of Therapeutic Efficacy in Pancreatic AdenocarcinomaLuigi Brancato, Damar Osok, Laurent Van den Bossche, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 23, 2013
Overlapping substrate and inhibitor specificity of human and murine ABCG2Joshua Bakhsheshian, Matthew D Hall, Robert W Robey, et al.
Blood|March 5, 2004
T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistanceRichard L Piekarz, Robert W Robey, Zhirong Zhan, et al.
Pageof 30